GoodRx Offers Wegovy Weight-Loss Pill at Under $150 a Month

GoodRx announced today that it has launched its sale of oral semaglutide (Wegovy) available at a cash price of $149 per month through its affiliated pharmacies, according to a news release.¹ This announcement comes just 2 weeks following the FDA’s approval of the landmark pill manufactured by Novo Nordisk.²

“We’re excited to help consumers access one of the most anticipated weight-loss treatments on the market,” Wendy Barnes, president and CEO of GoodRx, said in the news release.¹ “As new oral [glucagon-like peptide-1] (GLP-1) options emerge, GoodRx is uniquely positioned to support patients as they navigate their treatment choices.”

The benefits of GLP-1s have been exceedingly reported on in recent history, with experts oftentimes coining this prescription class as a “miracle drug.” However, upon discoveries in diabetes and cardiometabolic spaces, GLP-1s reached populations with obesity and overweight while also coming with significant out-of-pocket (OOP) expenses for patients.³

READ MORE: Wegovy Pill Receives FDA Approval as First Oral GLP-1 for Weight-Loss

With this GoodRx announcement, key decision-makers are celebrating their ability to come together and advocate for health care equity in the distribution of medications.

“This moment is about changing what’s possible in weight management, and to make that possible, we have worked to ensure the Wegovy pill is affordable and accessible to those who need it, however they choose to receive their care,” Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk, said to CNBC.⁴

How GoodRx is ‘Streamlining’ Patients’ Paths to Weight Loss

Through the newly announced Novo Nordisk and GoodRx partnership, the 2 companies will work together to distribute oral Wegovy to self-pay-eligible patients across the 70,000-plus pharmacies affiliated with GoodRx. The drug will be available in its 2 lowest doses (1.5 mg and 4 mg) offered at a cash price of $149 per month.¹

The company also announced the launch of GoodRx for Weight Loss, a telemedicine program designed to supplement patients’ prescription drug regimens with guidance and weight management support.

According to the release, all GoodRx-affiliated pharmacies will dispense 1.5 mg and 4 mg oral Wegovy at $149 per month through April 15, 2026. After this date, patients will pay $199 per month for 4 mg Wegovy, while the 9 mg and 25 mg options will round out at $299 per month.

Although these prices are certainly not universally accessible across populations, they are significantly more affordable than previous OOP costs for GLP-1s featuring various indications.

A History of High GLP-1 Spending

In a study published in the Journal of Managed Care and Specialty Pharmacy, researchers found the average annual per-person cost of GLP-1s to be $6947, which is equivalent to over $575 a month just for cardiometabolic treatment.⁵ With previous reports of GLP-1s constituting a main proportion of patients’ spending on diabetes care, they are now heavily prominent in the obesity space as more therapies reach the market, such as Novo’s new semaglutide pill.

On top of high patient spending, however, manufacturers and insurers have also increasingly invested in GLP-1 medications, which highlights the much-needed environment of competition and development many experts agreed was lacking in the prescription drug market.

“Of medications indicated for obesity at the time of the study, Saxenda (liraglutide) rose from $560 million in 2018 to $890 million in 2023,” wrote authors of an American Medical Association article.⁶ “Spending on Wegovy (the form of semaglutide indicated for obesity) grew from $580 million in 2021 to $6.99 billion by 2023.”

Looking Ahead for GoodRx and GLP-1s

GoodRx’s efforts at establishing the “new lowest discounted cash prices” for Wegovy demonstrate how some of the biggest players in the drug market are reacting to key trends in both the diabetes and obesity spaces.¹ These trends—from new insurance models for better access to competitive research and development—are expected to continue as experts and patients alike reap the benefits of GLP-1 medications.

Furthermore, these industry-shaking announcements are also occurring alongside the rise of pharmacists as trusted health care providers as well as pharmacies as convenient and community health care hubs.

With pharmacists, manufacturers, and insurers—and even the federal government—all working together to bring patients better options while simultaneously improving health, many are hopeful that these announcements and partnerships translate to better, more accessible patient outcomes.

“By combining transparent cash pricing with streamlined access to care and broad pharmacy availability, we're helping usher in a simpler, more consumer-friendly chapter in weight management treatment,” concluded Barnes in the release.¹

READ MORE: Obesity Management Resource Center

Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.

REFERENCES

1. GoodRx now offers Novo Nordisk’s cash price for the launch of the Wegovy® pill. News Release. GoodRx. January 5, 2025. Accessed January 5, 2025. https://www.businesswire.com/news/home/20260105738223/en/GoodRx-Now-Offers-Novo-Nordisks-Cash-Price-for-the-Launch-of-the-Wegovy-Pill

2. Nowosielski B. Wegovy pill receives FDA approval as first oral GLP-1 for weight loss. Drug Topics. December 23, 2025. Accessed January 5, 2025. https://www.drugtopics.com/view/wegovy-pill-receives-fda-approval-as-first-oral-weight-loss-drug

3. Dorrell M. Rx history: the rise of GLP-1s. Innovative Rx Strategies. January 25, 2024. Accessed January 5, 2025. https://innovativerxstrategies.com/rx-history-glp1s/

4. Constantino AK. First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. CNBC. January 5, 2025. Accessed January 5, 2025. https://www.cnbc.com/2026/01/05/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-us.html

5. Wu J, Perez A, Sullivan PW. Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes. J Manag Care Spec Pharm. 2025 Oct;31(10):1029-1038. doi: 10.18553/jmcp.2025.31.10.1029.

6. O’Reilly KB. Spending on GLP-1s has grown dramatically. Here are the details. American Medical Association. August 27, 2025. Accessed January 5, 2025. https://www.ama-assn.org/public-health/behavioral-health/spending-glp-1s-has-grown-dramatically-here-are-details